Welcome to our dedicated page for Instil Bio SEC filings (Ticker: TIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Instil Bio, Inc. (TIL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, with its lead asset AXN-2510, a PD-L1xVEGF bispecific antibody, in development for multiple solid tumors.
Instil Bio’s recent Form 8-K filings illustrate how the company uses current reports to communicate material information. Some 8-Ks reference results of operations and financial condition, where Instil furnishes press releases detailing quarterly financial results, operating expenses, and net losses. These filings often discuss research and development expenses, general and administrative expenses, restructuring and impairment charges, and the company’s use of non-GAAP financial measures such as non-GAAP net loss and non-GAAP net loss per share, which exclude non-cash stock-based compensation and restructuring and impairment charges.
Other 8-K filings focus on clinical and collaboration updates. For example, Instil Bio has filed an 8-K describing preliminary safety and efficacy data from ImmuneOnco Biopharmaceuticals (Shanghai) Inc.’s Phase 2 open-label, multicenter study of IMM2510/AXN-2510 in combination with chemotherapy for front-line advanced non-small cell lung cancer (NSCLC) in China. That filing summarizes partial response rates and safety observations, including the absence of dose-limiting toxicities and the nature of treatment-related adverse events.
Through these and other SEC filings, investors can review how Instil Bio reports its financial performance, presents reconciliations between GAAP and non-GAAP metrics, and discloses key developments related to AXN-2510 and its collaboration with ImmuneOnco. On Stock Titan, these documents are paired with AI-powered summaries that help explain the context and main points of each filing, making it easier to understand complex financial tables, clinical trial descriptions, and regulatory disclosures.
Instil Bio, Inc. (TIL) received an amended Schedule 13G filing showing that BML Investment Partners, L.P., a Delaware entity, beneficially owns 645,600 shares of Instil Bio common stock. This represents 9.5% of the outstanding common shares as of the event date.
BML reports shared voting and dispositive power over all 645,600 shares and no sole voting or dispositive power. The filing is certified as being made for investment purposes, not to change or influence control of Instil Bio.
Instil Bio, Inc. filed its Q3 2025 report, showing continued R&D investment and a narrower quarterly loss. The company reported a net loss of
Operating expenses were
Debt consisted of an outstanding principal of
Instil Bio, Inc. (TIL) furnished a corporate update and financial results for the quarter ended September 30, 2025, via an accompanying press release.
The update was provided under Item 2.02 and the information is being furnished, not filed. Detailed results are included in Exhibit 99.1 to the report.
Form 144 notice for Instil Bio, Inc. (TIL) reporting a proposed sale of common stock. The filing discloses a brokered sale through Morgan Stanley Smith Barney LLC on NASDAQ of 30,000 shares with an aggregate market value of $701,595, against total outstanding shares of 6,750,716. The securities were acquired and are proposed to be sold on 09/10/2025 following a stock option exercise, with payment made in cash on the acquisition date. The filer reports no other securities sold in the past three months and includes the required representation about material non-public information.
Instil Bio, Inc. reported a net loss of $21.4 million for the quarter and $49.6 million for the six months ended June 30, 2025, driven by increased R&D activity and restructuring and impairment charges of $16.6 million related to listing the Tarzana facility for sale. The company recognized a $10.0 million in-process R&D charge tied to a development milestone under its ImmuneOnco collaboration after IND clearance for AXN-2510/IMM2510 in the U.S.
The balance sheet shows $103.6 million of cash, cash equivalents, restricted cash, marketable securities and long-term investments and assets held for sale of $112.1 million (Tarzana). Debt includes a $85.6 million term loan (interest-only at 6.35%, two-year term). Management states current resources are expected to fund operations beyond 2026, and the company completed an ATM sale for $6.6 million in Q2.
Instil Bio, Inc. furnished an 8-K reporting a corporate update and its financial results for the quarter ended June 30, 2025. The company said the details appear in a press release filed as Exhibit 99.1 to the 8-K and that the information is being furnished (not "filed") under the Securities Exchange Act. No financial figures, operational details, or other substantive results are included in the 8-K text itself; readers are directed to the attached press release for the actual results.
Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P. reported beneficial ownership of 292,743 shares of Instil Bio, Inc. common stock, equal to 4.5% of the company based on 6,559,927 shares outstanding as disclosed May 9, 2025. The shares are held of record by Vivo Capital Fund IX, L.P., and Vivo Capital IX, LLC is the fund's general partner.
The Schedule 13G/A (Amendment No. 2), CUSIP 45783C200, shows the reporting persons have sole voting and dispositive power over the 292,743 shares and includes a certification that the position was not acquired to change or influence control. The filing is signed by Frank Kung on 08/12/2025.
FAQ
What is the current stock price of Instil Bio (TIL)?
What is the market cap of Instil Bio (TIL)?
